

AMENDMENTS TO THE CLAIMS

Please cancel claims 1-4 in their entirety, and add new claims 5-53, as follows:

Claims 1-4 (Cancelled).

Claim 5 (New) A liposomal composition comprising:

a glycoside exhibiting antitumor activity, wherein said glycoside comprises:

a sugar moiety selected from the group consisting of GlcNAc-Gal-,

GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, and Gal-; and

a hydrophobic compound;

a phospholipid; and

a positive-charge-providing substance,

wherein said phospholipid and said positive-charge-providing substance are capable of forming a liposome.

Claim 6 (New) The liposomal composition according to claim 5, wherein said hydrophobic compound is a hydrophobic aglycon.

Claim 7 (New) The liposomal composition according to claim 5, wherein said hydrophobic compound is selected from the group consisting of cholestanol, naphthalene methanol, and ceramide.

Claim 8 (New) The liposomal composition according to claim 7, wherein said hydrophobic compound is cholestanol.

Claim 9 (New) The liposomal composition according to claim 7, wherein said hydrophobic compound is naphthalene methanol.

Claim 10 (New) The liposomal composition according to claim 7, wherein said hydrophobic compound is ceramide.

Claim 11 (New) The liposomal composition according to claim 5, wherein said phospholipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and phosphatidic acid.

Claim 12 (New) The liposomal composition according to claim 11, wherein said phospholipid is a phosphatidylcholine selected from the group consisting of dilaurylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, dilinoleoylphosphatidylcholine, myristoylpalmitoylphosphatidylcholine, myristoylstearoylphosphatidylcholine, and palmitoylarachidoylphosphatidylcholine.

Claim 13 (New) The liposomal composition according to claim 12, wherein said phosphatidylcholine is dipalmitoylphosphatidylcholine.

Claim 14 (New) The liposomal composition according to claim 5, wherein said positive-charge-providing substance is an aliphatic amine.

Claim 15 (New) The liposomal composition according to claim 14, wherein said aliphatic amine is stearylamine.

Claim 16 (New) The liposomal composition according to claim 14, wherein said aliphatic amine is oleylamine.


Claim 17 (New) The liposomal composition according to claim 5, wherein said positive-charge-providing substance is an aromatic amine.

Claim 18 (New) The liposomal composition according to claim 17, wherein said aromatic amine is fluoreneethylamine.

Claim 19 (New) An anticancer agent comprising:
the liposomal composition according to claim 5; and
one or more pharmaceutically acceptable additives selected from the group consisting of excipients, carriers, binders, disintegrating agents, lubricants, humectants, colorants, flavorants, deodorants, preservatives, stabilizers, pH adjusters, buffers, isotonicity-imparting agents, water, surfactants, and anesthetic agents.

Claim 20 (New) The anticancer agent according to claim 19, wherein said anticancer agent is formulated in a dosage form selected from the group consisting of a peroral solid, a peroral liquid, an injection, a suppository, an ointment, and a patch.

Claim 21 (New) A liposomal composition comprising:
a glycoside exhibiting antitumor activity, wherein said glycoside is represented by a compound of formula (1):



a phospholipid; and

a positive-charge-providing substance,

wherein G represents a sugar moiety selected from the group consisting of

GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, and Gal-,

wherein said phospholipid and said positive-charge-providing substance are capable of forming a liposome.

Claim 22 (New) The liposomal composition according to claim 21, wherein said phospholipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and phosphatidic acid.

Claim 23 (New) The liposomal composition according to claim 22, wherein said phospholipid is a phosphatidylcholine selected from the group consisting of dilaurylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, dilinoleoylphosphatidylcholine, myristoylpalmitoylphosphatidylcholine, myristoylstearylphosphatidylcholine, and palmitoylarachidoylphosphatidylcholine.

Claim 24 (New) The liposomal composition according to claim 23, wherein said phosphatidylcholine is dipalmitoylphosphatidylcholine.

Claim 25 (New) The liposomal composition according to claim 21, wherein said positive-charge-providing substance is an aliphatic amine.

Claim 26 (New) The liposomal composition according to claim 25, wherein said aliphatic amine is stearylamine.

Claim 27 (New) The liposomal composition according to claim 25, wherein said aliphatic amine is oleylamine.

Claim 28 (New) The liposomal composition according to claim 21, wherein said positive-charge-providing substance is an aromatic amine.


Claim 29 (New) The liposomal composition according to claim 28, wherein said aromatic amine is fluoreneethylamine.

Claim 30 (New) An anticancer agent comprising:
the liposomal composition according to claim 21; and
one or more pharmaceutically acceptable additives selected from the group consisting of excipients, carriers, binders, disintegrating agents, lubricants, humectants, colorants, flavorants, deodorants, preservatives, stabilizers, pH adjusters, buffers, isotonicity-imparting agents, water, surfactants, and anesthetic agents.

Claim 31 (New) The anticancer agent according to claim 30, wherein said anticancer agent is formulated in a dosage form selected from the group consisting of a peroral solid, a peroral liquid, an injection, a suppository, an ointment, and a patch.

Claim 32 (New) A liposomal composition comprising:

a glycoside exhibiting antitumor activity, wherein said glycoside is represented by a compound of formula (2):



a phospholipid; and

a positive-charge-providing substance,

wherein G represents a sugar moiety selected from the group consisting of GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, and Gal-, wherein said phospholipid and said positive-charge-providing substance are capable of forming a liposome.

Claim 33 (New) The liposomal composition according to claim 32, wherein said phospholipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and phosphatidic acid.

Claim 34 (New) The liposomal composition according to claim 33, wherein said phospholipid is a phosphatidylcholine selected from the group consisting of dilaurylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine,

dilinoleoylphosphatidylcholine, myristoylpalmitoylphosphatidylcholine,
myristoylstearylphosphatidylcholine, and palmitoylarchidoylphosphatidylcholine.

Claim 35 (New) The liposomal composition according to claim 34, wherein said phosphatidylcholine is dipalmitoylphosphatidylcholine.

Claim 36 (New) The liposomal composition according to claim 32, wherein said positive-charge-providing substance is an aliphatic amine.

Claim 37 (New) The liposomal composition according to claim 36, wherein said aliphatic amine is stearylamine.

Claim 38 (New) The liposomal composition according to claim 36, wherein said aliphatic amine is oleylamine.

Claim 39 (New) The liposomal composition according to claim 32, wherein said positive-charge-providing substance is an aromatic amine.

Claim 40 (New) The liposomal composition according to claim 39, wherein said aromatic amine is fluoreneethylamine.


Claim 41 (New) An anticancer agent comprising:
the liposomal composition according to claim 32; and
one or more pharmaceutically acceptable additives selected from the group consisting of excipients, carriers, binders, disintegrating agents, lubricants, humectants, colorants,

flavorants, deodorants, preservatives, stabilizers, pH adjusters, buffers, isotonicity-imparting agents, water, surfactants, and anesthetic agents.

Claim 42 (New) The anticancer agent according to claim 41, wherein said anticancer agent is formulated in a dosage form selected from the group consisting of a peroral solid, a peroral liquid, an injection, a suppository, an ointment, and a patch.

Claim 43 (New) A liposomal composition comprising:

a glycoside exhibiting antitumor activity, wherein said glycoside is represented by a compound of formula (3):



a phospholipid; and

a positive-charge-providing substance,

wherein G represents a sugar moiety selected from the group consisting of GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, and Gal-, wherein n represents an integer of from 12 to 26, wherein said phospholipid and said positive-charge-providing substance are capable of forming a liposome.

Claim 44 (New) The liposomal composition according to claim 43, wherein said phospholipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and phosphatidic acid.

Claim 45 (New) The liposomal composition according to claim 44, wherein said phospholipid is a phosphatidylcholine selected from the group consisting of dilaurylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, dilinoleoylphosphatidylcholine, myristoylpalmitoylphosphatidylcholine, myristoylstearylphosphatidylcholine, and palmitoylarachidoylphosphatidylcholine.

Claim 46 (New) The liposomal composition according to claim 45, wherein said phosphatidylcholine is dipalmitoylphosphatidylcholine.

Claim 47 (New) The liposomal composition according to claim 43, wherein said positive-charge-providing substance is an aliphatic amine.

Claim 48 (New) The liposomal composition according to claim 47, wherein said aliphatic amine is stearylamine.

Claim 49 (New) The liposomal composition according to claim 47, wherein said aliphatic amine is oleylamine.

Claim 50 (New) The liposomal composition according to claim 43, wherein said positive-charge-providing substance is an aromatic amine.

Claim 51 (New) The liposomal composition according to claim 50, wherein said aromatic amine is fluoreneethylamine.

Claim 52 (New) An anticancer agent comprising:
the liposomal composition according to claim 43; and
one or more pharmaceutically acceptable additives selected from the group consisting of excipients, carriers, binders, disintegrating agents, lubricants, humectants, colorants, flavorants, deodorants, preservatives, stabilizers, pH adjusters, buffers, isotonicity-imparting agents, water, surfactants, and anesthetic agents.

Claim 53 (New) The anticancer agent according to claim 52, wherein said anticancer agent is formulated in a dosage form selected from the group consisting of a peroral solid, a peroral liquid, an injection, a suppository, an ointment, and a patch.